Scioto Biosciences

What it does

"Scioto Biosciences is a pioneering health and lifetech company focused on developing innovative therapies with a transformative impact on microbiome therapeutics. Founded in 2017 and headquartered in Indianapolis, Indiana, Scioto Biosciences is dedicated to revolutionizing the delivery of microbiome-based treatments. At the core of their mission is the Scioto Platform, designed to enhance the efficacy of probiotics in various applications, including diabetes, neurological disorders, gastrointestinal health, and livestock health. Central to Scioto's advancements is their proprietary Activated Bacterial Therapeutics (ABT) platform, which optimizes the delivery and functionality of live bacterial therapeutics. Their lead product candidate, SB-121, utilizes this platform to target specific conditions like Autism Spectrum Disorder and necrotizing enterocolitis. In 2020, Scioto Biosciences secured a significant Series B investment from Genome & Company, a South Korean firm, further solidifying their position in the industry and expanding their developmental capabilities."